Pelotonia Institute for Immuno-Oncology shared a post on X:
“We’re celebrating IND approval for the first in human PIIO-1 trial — a groundbreaking CAR-T Cell Therapy for recurrent glioblastoma!
This novel approach targets GARP and delivers engineered T cells directly into the tumor.
A major milestone for GBM research and immunotherapy!”
More posts featuring Pelotonia Institute for Immuno-Oncology.
